Evidence map›Paper›PMID 39344184›Full record

ArticleJournal of medicinal chemistry2024

Distinctive Immune Signatures Driven by Structural Alterations in Desmuramylpeptide NOD2 Agonists.

Špela Janež, Samo Guzelj, Petra Kocbek, Eveline A de Vlieger, Bram Slütter, Žiga Jakopin

Abstract read
In one paragraph

Article in Journal of medicinal chemistry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Trial
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Špela JanežFaculty of Pharmacy, University of Ljubljana, SI-1000 Ljubljana, Slovenia.
Samo GuzeljFaculty of Pharmacy, University of Ljubljana, SI-1000 Ljubljana, Slovenia.
Petra KocbekFaculty of Pharmacy, University of Ljubljana, SI-1000 Ljubljana, Slovenia.ORCID 0000-0002-6778-3295
Eveline A de VliegerDiv. BioTherapeutics, Leiden Academic Centre for Drug Research, Leiden University, 2333 CC Leiden, The Netherlands.ORCID 0009-0007-3663-5103
Bram SlütterDiv. BioTherapeutics, Leiden Academic Centre for Drug Research, Leiden University, 2333 CC Leiden, The Netherlands.
Žiga JakopinFaculty of Pharmacy, University of Ljubljana, SI-1000 Ljubljana, Slovenia.ORCID 0000-0001-9384-0858

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Herein we report on the design, synthesis and biological evaluation of a series of nucleotide-binding oligomerization-domain-containing protein 2 (NOD2) desmuramylpeptide agonists. The structural prerequisites that shape both physicochemical and immunomodulatory profiles of desmuramylpeptide NOD2 agonists have been delineated. Within this context, we identified

Indexed as

Leukocytes, MononuclearLipopolysaccharidesNod2 Signaling Adaptor ProteinAnimalsCytokinesDendritic CellsHumansK562 CellsMiceMice, Inbred C57BLStructure-Activity RelationshipCytokinesLipopolysaccharidesNOD2 protein, humanNod2 Signaling Adaptor Protein

Identifiers

PMID39344184
PMCPMC11472310

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.